Search

Your search keyword '"Bormans, Guy"' showing total 1,211 results
Start Over Author "Bormans, Guy"
1,211 results on '"Bormans, Guy"'

1. Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Author

DaSilva, Jean, Decristoforo, Clemens, Mach, Robert, Bormans, Guy, Carlucci, Giuseppe, Al-Qahtani, Mohammed, Duatti, Adriano, Gee, Antony, Szymanski, Wiktor, Rubow, Sietske, Hendrikx, Jeroen, Yang, Xing, Jia, Hongmei, Zhang, Junbo, Caravan, Peter, Yang, Hua, Zeevaart, Jan, Rodriquez, Miguel, Oliveira, Ralph, Zubillaga, Marcela, Sakr, Tamer, and Spreckelmeyer, Sarah

Subjects
Highlight articles, Nuclear medicine, Radiochemistry, Radiopharmaceutical sciences, Radiopharmacy, Trends in radiopharmaceutical sciences
Abstract

BACKGROUND: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. MAIN BODY: This selection of highlights provides commentary on 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals. CONCLUSION: Trends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field in many aspects.

Published
2023

3. Author Correction: Reverse engineering synthetic antiviral amyloids

Author

Michiels, Emiel, Roose, Kenny, Gallardo, Rodrigo, Khodaparast, Ladan, Khodaparast, Laleh, van der Kant, Rob, Siemons, Maxime, Houben, Bert, Ramakers, Meine, Wilkinson, Hannah, Guerreiro, Patricia, Louros, Nikolaos, Kaptein, Suzanne J. F., Ibañez, Lorena Itatí, Smet, Anouk, Baatsen, Pieter, Liu, Shu, Vorberg, Ina, Bormans, Guy, Neyts, Johan, Saelens, Xavier, Rousseau, Frederic, and Schymkowitz, Joost

Published
2023
Full Text
View/download PDF

7. Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Author

Aime, Silvio, Al-Qahtani, Mohammed, Behe, Martin, Bormans, Guy, Carlucci, Giuseppe, DaSilva, Jean, Decristoforo, Clemens, Duatti, Adriano, Elsinga, Philip, Kopka, Klaus, Li, Xiang-Guo, Liu, Zhibo, Mach, Robert, Middel, Oskar, Passchier, Jan, Patt, Marianne, Penuelas, Ivan, Rey, Ana, Scott, Peter, Todde, Sergio, Toyohara, Jun, Vugts, Danielle, and Yang, Zhi

Abstract

BACKGROUND: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. RESULTS: This commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals. CONCLUSION: Trends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.

Published
2021

8. Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January-June 2020).

Author

Al-Qahtani, Mohammed, Behe, Martin, Bormans, Guy, Carlucci, Giuseppe, Dasilva, Jean, Decristoforo, Clemens, Elsinga, Philip, Kopka, Klaus, Li, Xiang-Guo, Mach, Robert, Middel, Oskar, Passchier, Jan, Patt, Marianne, Penuelas, Ivan, Rey, Ana, Scott, Peter, Todde, Sergio, Toyohara, Jun, and Vugts, Danielle

Abstract

BACKGROUND: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to describe trends in the field. RESULTS: This commentary of highlights has resulted in 19 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals. CONCLUSION: Trends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.

Published
2021

12. Clinical impact of using [18F]AlF‐NOTA‐octreotide PET/CT instead of [68Ga]Ga‐DOTA‐SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial

Author

Leupe, Hannes, primary, Pauwels, Elin, additional, Vandamme, Timon, additional, Van den Broeck, Bliede, additional, Lybaert, Willem, additional, Dekervel, Jeroen, additional, Van Herpe, Filip, additional, Jaekers, Joris, additional, Cleeren, Frederik, additional, Hofland, Johannes, additional, Brouwers, Adrienne, additional, Koole, Michel, additional, Bormans, Guy, additional, Van Cutsem, Eric, additional, Geboes, Karen, additional, Laenen, Annouschka, additional, Verslype, Chris, additional, Stroobants, Sigrid, additional, and Deroose, Christophe M., additional

Published
2024
Full Text
View/download PDF

16. Clinical impact of using [18F]AlF‐NOTA‐octreotide PET/CT instead of [68Ga]Ga‐DOTA‐SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial.

Author

Leupe, Hannes, Pauwels, Elin, Vandamme, Timon, Van den Broeck, Bliede, Lybaert, Willem, Dekervel, Jeroen, Van Herpe, Filip, Jaekers, Joris, Cleeren, Frederik, Hofland, Johannes, Brouwers, Adrienne, Koole, Michel, Bormans, Guy, Van Cutsem, Eric, Geboes, Karen, Laenen, Annouschka, Verslype, Chris, Stroobants, Sigrid, and Deroose, Christophe M.

Subjects
POSITRON emission tomography, SOMATOSTATIN receptors, COMPUTED tomography, NEUROENDOCRINE tumors, SECONDARY analysis
Abstract

[18F]AlF‐NOTA‐octreotide ([18F]AlF‐OC) is a promising alternative for [68Ga]Ga‐DOTA‐somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the somatostatin receptor (SSTR). Our aim is to assess changes in TNM staging and differences in patient management between [18F]AlF‐OC PET/CT and [68Ga]Ga‐DOTA‐SSA PET/CT in the work‐up of neuroendocrine tumor (NET) patients. Patients who underwent both [18F]AlF‐OC and [68Ga]Ga‐DOTA‐TATE or [68Ga]Ga‐DOTA‐NOC PET/CT in our multicenter study (Pauwels et al., J Nucl Med.2023;63:632–638) with a NET were included for analysis. TNM staging was determined and compared for both tracers. For each patient, the blinded [68Ga]Ga‐DOTA‐SSA or [18F]AlF‐OC PET/CT images were presented in random order at a multidisciplinary team board. The images were presented together with clinical information and compared with previous SSTR and [18F]FDG PET/CT imaging. After a consensus decision for patient management was recorded, the board was presented with the PET/CT images from the other SSTR tracer and a decision was made for the second tracer. Differences in management were classified as major if it entailed an intermodality change and minor if it led to an intramodality change. Compared with [68Ga]Ga‐DOTA‐SSA, the use of [18F]AlF‐OC led to a change in 16/75 patients: TNM staging changes in 10/75 patients (13.3%; downstaging in 3/10, upstaging in 7/10) and differences in clinical management were seen in 10/75 patients (13.3%), leading to a major difference in 7/10 cases and a minor change in 3/10 cases. All 10 cases with a difference in patient management between both PET tracers were caused by additional lesion detection by [18F]AlF‐OC. The use of [18F]AlF‐OC did not impact TNM staging or clinical management in the large majority of the patients (86.7%), further validating the potential for routine clinical use of [18F]AlF‐OC PET/CT as an alternative for [68Ga]Ga‐DOTA‐SSA PET/CT. The trial is registered under ClinicalTrials.gov identifier NCT04552847 and EudraCT 2020–000549‐15. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Synthesis, Structure–Activity Relationships, Radiofluorination, and Biological Evaluation of [18F]RM365, a Novel Radioligand for Imaging the Human Cannabinoid Receptor Type 2 (CB2R) in the Brain with PET

Author

Teodoro, Rodrigo, primary, Gündel, Daniel, additional, Deuther-Conrad, Winnie, additional, Kazimir, Aleksandr, additional, Toussaint, Magali, additional, Wenzel, Barbara, additional, Bormans, Guy, additional, Hey-Hawkins, Evamarie, additional, Kopka, Klaus, additional, Brust, Peter, additional, and Moldovan, Rareş-Petru, additional

Published
2023
Full Text
View/download PDF

36. Reverse engineering synthetic antiviral amyloids

Author

Michiels, Emiel, Roose, Kenny, Gallardo, Rodrigo, Khodaparast, Ladan, Khodaparast, Laleh, van der Kant, Rob, Siemons, Maxime, Houben, Bert, Ramakers, Meine, Wilkinson, Hannah, Guerreiro, Patricia, Louros, Nikolaos, Kaptein, Suzanne J. F., Ibañez, Lorena Itatí, Smet, Anouk, Baatsen, Pieter, Liu, Shu, Vorberg, Ina, Bormans, Guy, Neyts, Johan, Saelens, Xavier, Rousseau, Frederic, and Schymkowitz, Joost

Published
2020
Full Text
View/download PDF

37. Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients

Author

Boeckxstaens, Lennert, primary, Pauwels, Elin, additional, Vandecaveye, Vincent, additional, Deckers, Wies, additional, Cleeren, Frederik, additional, Dekervel, Jeroen, additional, Vandamme, Timon, additional, Serdons, Kim, additional, Koole, Michel, additional, Bormans, Guy, additional, Laenen, Annouschka, additional, Clement, Paul M., additional, Geboes, Karen, additional, Van Cutsem, Eric, additional, Nackaerts, Kristiaan, additional, Stroobants, Sigrid, additional, Verslype, Chris, additional, Van Laere, Koen, additional, and Deroose, Christophe M., additional

Published
2023
Full Text
View/download PDF

38. De novo design of a biologically active amyloid

Author

Gallardo, Rodrigo, Ramakers, Meine, De Smet, Frederik, Claes, Filip, Khodaparast, Ladan, Khodaparast, Laleh, Couceiro, José R., Langenberg, Tobias, Siemons, Maxime, Nyström, Sofie, Young, Laurence J., Laine, Romain F., Young, Lydia, Radaelli, Enrico, Benilova, Iryna, Kumar, Manoj, Staes, An, Desager, Matyas, Beerens, Manu, Vandervoort, Petra, Luttun, Aernout, Gevaert, Kris, Bormans, Guy, Dewerchin, Mieke, Van Eldere, Johan, Carmeliet, Peter, Vande Velde, Greetje, Verfaillie, Catherine, Kaminski, Clemens F., De Strooper, Bart, Hammarström, Per, Peter, K., Nilsson, R., Serpell, Louise, Schymkowitz, Joost, and Rousseau, Frederic

Published
2016

43. Guidelines for the content and format of PET brain data in publications and archives: A consensus paper

Author

Knudsen, Gitte M, Ganz, Melanie, Appelhoff, Stefan, Boellaard, Ronald, Bormans, Guy, Carson, Richard E, Catana, Ciprian, Doudet, Doris, Gee, Antony D, Greve, Douglas N, Gunn, Roger N, Halldin, Christer, Herscovitch, Peter, Huang, Henry, Keller, Sune H, Lammertsma, Adriaan A, Lanzenberger, Rupert, Liow, Jeih-San, Lohith, Talakad G, Lubberink, Mark, Lyoo, Chul H, Mann, J John, Matheson, Granville J, Nichols, Thomas E, Nørgaard, Martin, Ogden, Todd, Parsey, Ramin, Pike, Victor W, Price, Julie, Rizzo, Gaia, Rosa-Neto, Pedro, Schain, Martin, Scott, Peter JH, Searle, Graham, Slifstein, Mark, Suhara, Tetsuya, Talbot, Peter S, Thomas, Adam, Veronese, Mattia, Wong, Dean F, Yaqub, Maqsood, Zanderigo, Francesca, Zoghbi, Sami, and Innis, Robert B

Published
2020
Full Text
View/download PDF

44. Prospective comparison of [F-18]AlF-NOTA-octreotide PET/MRI to [Ga-68]Ga-DOTATATE PET/CT in neuroendocrine tumor patients

Author

Boeckxstaens, Lennert, Pauwels, Elin, Vandecaveye, Vincent, Deckers, Wies, Cleeren, Frederik, Dekervel, Jeroen, Vandamme, Timon, Serdons, Kim, Koole, Michel, Bormans, Guy, Laenen, Annouschka, Clement, Paul M, Geboes, Karen, Van Cutsem, Eric, Nackaerts, Kristiaan, Stroobants, Sigrid, Verslype, Chris, Van Laere, Koen, and Deroose, Christophe M

Subjects
PET/MR, PET, Neuroendocrine tumor, [68Ga]Ga-DOTATATE, [18F]AlF-NOTA-octreotide, Somatostatin receptor
Abstract

BACKGROUND: Fluorine-18-labeled SSAs have the potential to become the next-generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their logistical advantages over the current gold standard gallium-68-labeled SSAs. In particular, [18F]AlF-OC has already shown excellent clinical performance. We demonstrated in our previous report from our prospective multicenter trial that [18F]AlF-OC PET/CT outperforms [68Ga]Ga-DOTA-SSA, but histological confirmation was lacking due to ethical and practical reasons. In this second arm, we therefore aimed to provide evidence that the vast majority of [18F]AlF-OC PET lesions are in fact true NET lesions by analyzing their MR characteristics on simultaneously acquired MRI. We had a special interest in lesions solely detected by [18F]AlF-OC ("incremental lesions"). METHODS: Ten patients with a histologically confirmed neuroendocrine tumor (NET) and a standard-of-care [68Ga]Ga-DOTATATE PET/CT, performed within 3 months, were prospectively included. Patients underwent a whole-body PET/MRI (TOF, 3 T, GE Signa), 2 hours after IV injection of 4 MBq/kg [18F]AlF-OC. Positive PET lesions were evaluated for a corresponding lesion on MRI. The diagnostic performance of both PET tracers was evaluated by determining the detection ratio (DR) for each scan and the differential detection ratio (DDR) per patient. RESULTS: In total, 195 unique lesions were detected: 167 with [68Ga]Ga-DOTATATE and 193 with [18F]AlF-OC. The DR for [18F]AlF-OC was 99.1% versus 91.4% for [68Ga]Ga-DOTATATE, significant for non-inferiority testing (p = 0.0001). Out of these 193 [18F]AlF-OC lesions, 96.2% were confirmed by MRI to be NET lesions. Thirty-three incremental lesions were identified by [18F]AlF-OC, of which 91% were confirmed by MRI and considered true positives. CONCLUSION: The DR of [18F]AlF-OC was numerically higher and non-inferior to the DR of [68Ga]Ga-DOTATATE. [18F]AlF-OC lesions and especially incremental lesions were confirmed as true positives by MRI in more than 90% of lesions. Taken together, these data further validate [18F]AlF-OC as a new alternative for SSTR PET in clinical practice. Trial registration ClinicalTrials.gov: NCT04552847. Registered 17 September 2020, https://beta. CLINICALTRIALS: gov/study/NCT04552847. ispartof: EJNMMI RESEARCH vol:13 issue:1 ispartof: location:Germany status: published

Published
2023

49. ¹⁸F-AlF-NOTA-octreotide outperforms ⁶⁸Ga-DOTA-TATE/-NOC PET in neuroendocrine tumor patients : results from a prospective, multicenter study

Author

Pauwels, Elin, Cleeren, Frederik, Tshibangu, Térence, Koole, Michel, Serdons, Kim, Boeckxstaens, Lennert, Dekervel, Jeroen, Vandamme, Timon, Lybaert, Willem, Van den Broeck, Bliede, Laenen, Annouschka, Clement, Paul M., Geboes, Karen, Van Cutsem, Eric, Stroobants, Sigrid, Verslype, Chris, Bormans, Guy, and Deroose, Christophe M.

Subjects
Computer. Automation, Human medicine
Abstract

Fluorine-18-labeled somatostatin analogs (SSAs) could represent a valid alternative to the current gold standard gallium-68-labeled SSAs for somatostatin receptor (SSTR) imaging in patients with neuroendocrine tumors (NETs), given their logistical advantages. Recently, 18F-AlF-NOTA-octreotide (18F-AlF-OC) has emerged as a promising candidate, but a thorough comparison with 68Ga-DOTA-SSA in large patient groups is needed. This prospective, multicenter trial aims to demonstrate non-inferiority of 18F-AlF-OC compared with 68Ga-DOTA-SSA PET in NET patients (ClinicalTrials.gov: NCT04552847). Methods: Seventy-five patients with histologically confirmed NET and a routine clinical 68Ga-DOTATATE (n = 56) or 68Ga-DOTANOC (n = 19) PET, performed within a 3-month interval of the study scan (median: 7 days; range: -30 to +32 days), were included. Patients underwent a whole-body PET, two hours after IV injection of 4 MBq/kg 18F-AlF-OC. A randomized, blinded consensus read was performed by two experienced readers to count tumor lesions. Following unblinding, the detection ratio (DR) was determined for each scan, i.e. the fraction of lesions detected on a scan compared to the union of lesions of both scans. The differential detection ratio (DDR; difference in DR between 18F-AlF-OC and 68Ga-DOTATATE/NOC) per patient was calculated. Tracer uptake was evaluated by comparing SUVmax and tumor-to-background ratios (TBRs) in concordant lesions. Results: In total, 4709 different tumor lesions were detected, 3454 with 68Ga-DOTATATE/NOC and 4278 with 18F-AlF-OC. The mean DR with 18F-AlF-OC was significantly higher than with 68Ga-DOTATATE/NOC (91.1% vs. 75.3%; P

Published
2023

50. Prospective comparison of [¹⁸F]AlF-NOTA-octreotide PET/MRI to [⁶⁸Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients

Author

Boeckxstaens, Lennert, Pauwels, Elin, Vandecaveye, Vincent, Deckers, Wies, Cleeren, Frederik, Dekervel, Jeroen, Vandamme, Timon, Serdons, Kim, Koole, Michel, Bormans, Guy, Laenen, Annouschka, Clement, Paul M., Geboes, Karen, Van Cutsem, Eric, Nackaerts, Kristiaan, Stroobants, Sigrid, Verslype, Chris, Van Laere, Koen, and Deroose, Christophe M.

Subjects
Computer. Automation, Human medicine
Abstract

Background Fluorine-18-labeled SSAs have the potential to become the next-generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their logistical advantages over the current gold standard gallium-68-labeled SSAs. In particular, [F-18]AlF-OC has already shown excellent clinical performance. We demonstrated in our previous report from our prospective multicenter trial that [F-18]AlF-OC PET/CT outperforms [Ga-68]Ga-DOTA-SSA, but histological confirmation was lacking due to ethical and practical reasons. In this second arm, we therefore aimed to provide evidence that the vast majority of [F-18]AlF-OC PET lesions are in fact true NET lesions by analyzing their MR characteristics on simultaneously acquired MRI. We had a special interest in lesions solely detected by [F-18]AlF-OC ("incremental lesions").Methods Ten patients with a histologically confirmed neuroendocrine tumor (NET) and a standard-of-care [Ga-68]Ga-DOTATATE PET/CT, performed within 3 months, were prospectively included. Patients underwent a whole-body PET/MRI (TOF, 3 T, GE Signa), 2 hours after IV injection of 4 MBq/kg [F-18]AlF-OC. Positive PET lesions were evaluated for a corresponding lesion on MRI. The diagnostic performance of both PET tracers was evaluated by determining the detection ratio (DR) for each scan and the differential detection ratio (DDR) per patient.Results In total, 195 unique lesions were detected: 167 with [Ga-68]Ga-DOTATATE and 193 with [F-18]AlF-OC. The DR for [F-18]AlF-OC was 99.1% versus 91.4% for [Ga-68]Ga-DOTATATE, significant for non-inferiority testing (p = 0.0001). Out of these 193 [F-18]AlF-OC lesions, 96.2% were confirmed by MRI to be NET lesions. Thirty-three incremental lesions were identified by [F-18]AlF-OC, of which 91% were confirmed by MRI and considered true positives.Conclusion The DR of [F-18]AlF-OC was numerically higher and non-inferior to the DR of [Ga-68]Ga-DOTATATE. [F-18]AlF-OC lesions and especially incremental lesions were confirmed as true positives by MRI in more than 90% of lesions. Taken together, these data further validate [F-18]AlF-OC as a new alternative for SSTR PET in clinical practice.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results